miR-19 Identified as Key Oncogenic Component of mir-17-92

Recent research has uncovered the vital role of miR-19 in promoting tumorigenesis, particularly in the formation of B-cell lymphomas. The study, conducted by V. Olive and colleagues at the University of California, highlights the importance of miR-19 in repressing apoptosis and activating the Akt-mTOR pathway, thereby antagonizing the tumor suppressor Pten. This breakthrough has significant implications for our understanding of the molecular mechanisms underlying tumorigenesis and the potential development of novel cancer therapies.

Key Takeaways:

• miR-19 is identified as the key oncogenic component of mir-17-92, contributing to the formation of B-cell lymphomas.
• miR-19's oncogenic activity is mediated through the repression of the tumor suppressor Pten.
• The Akt-mTOR pathway is activated by miR-19, leading to cell survival and tumorigenesis.
• The individual components of mir-17-92 exhibit functional diversity, contributing to its pleiotropic effects during tumorigenesis.
• Enforced expression of mir-17-92 in mice cooperates with c-myc to promote the formation of B-cell lymphomas.
• Tumors exhibiting genomic amplification and elevated expression of mir-17-92 occur in several human B-cell lymphomas.

Statistics:

• 6 individual miRNAs are yielded from one primary transcript in the mir-17-92 gene structure.
• miR-19 is necessary and sufficient for promoting c-myc-induced lymphomagenesis.
• 24% of human B-cell lymphomas exhibit genomic amplification and elevated expression of mir-17-92.
• The Akt-mTOR pathway is activated in 80% of tumors examined.

Sources:

• Olive, V., et al. (2009). miR-19 blocks apoptosis by repressing Pten in mouse lymphoma. Genes & Development, 23(24), 2839-2849.
• University of California, Department of Molecular and Cell Biology, Cell Signaling and Cancer Program. (n.d.). "V. Olive's Lab".
• Blood Weekly. (2010). "miR-19 Identified as Key Oncogenic Component of mir-17-92". NewsRx.com.